Fc region variants

• US 20060153838A1
• Filed: 03/17/2006
• Published: 07/13/2006
• Est. Priority Date: 02/20/2002
• Status: Abandoned Application

• Current Assignee: Barrett Allan, Jeffry D. Watkins
• Original Assignee: Barrett Allan, Jeffry D. Watkins
• Inventors: Watkins, Jeffry D., Allan, Barrett
• Application Number:
  US11/384,134
• Publication Number:
  US 20060153838A1
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2317/524 CH2 domain
• CPC Class Codes: C07K 2317/72 Increased effector function due to an Fc-modification
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

The present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provided compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.

Claims

1. A variant antibody of a parent antibody comprising a human IgG Fc region, which variant comprises an amino acid substitution selected from the group consisting of 294N, 295K, 295L, 296P, 298N, 298V, 298D, 298P, 300I and 300L.

2. The composition of claim 1, wherein said variant antibody interacts with Fc gamma receptor III (Fcγ

RIII) with a higher binding affinity than said parent antibody.

3. The variant antibody of claim 1, wherein said variant antibody comprises an unmodified human framework region.

4. The variant antibody of claim 1, wherein said variant antibody is an anti-CD20 antibody.

5. The variant antibody claim 1, wherein said parent antibody comprises a human IgG1, IgG2, IgG3, or IgG4 Fc region.

6. The composition of claim 1, wherein said parent antibody comprises a CH2 region comprising SEQ ID NO:

23.